Ischemic Heart DiseaseNCT07579624
AI-Enhanced Single-Lead ECG Screening for Coronary Stenosis
An observational study of Ischemic Heart Disease and Coronary Artery Stenosis, run by I.M. Sechenov First Moscow State Medical University at 1 site in Russia.
Trial summary
It is a prospective, controlled, single-center, non-randomized, observational study. Two patient groups are planned for inclusion: the first - 200 patients with significant coronary artery stenosis confirmed by coronary angiography (CAG) or multislice computed tomography (MSCT) results; the second - a control group… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Ischemic Heart Disease, Coronary Artery Stenosis, Stable Angina Pectoris
- What is being tested?
- single-channel electrocardiogram
- How many people
- 400 participants
- Where
- 1 siteRussia
- Study dates
- 1 May 2026to 1 Dec 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: All study subjects will have a date of coronary artery imaging via CAG or MSCT with assessment of myocardial perfusion. Stress echocardiography tests or fractional flow reserve (FFR) assessment will be conducted as clinically indicated. ECG registration in standard lead I will be performed within 3 months before or after the CAG or MSCT.
Who may be able to join
- Presence of written informed consent from the patient to participate in the study.
- Age 18 years and older.
- Outpatient visit and/or hospitalization at the research center with coronary visualization performed.
- Non-inclusion criteria:
- Absence of sufficient data on coronary anatomy and stenosis significance.
- Any conditions impairing the quality of single-channel ECG recording (Parkinson's disease, essential tremor, and others).
- Absence of written informed consent from the patient to participate in the study.
Who cannot join
- Patient's unwillingness to continue participation in the study.
- Inability to perform full analysis of single-channel ECG digital characteristics.
- Refusal of coronary visualization methods for any reason.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Screening for Significant Coronary Artery Stenosis Using Single-channel Electrocardiogram Analysis With Artificial Intelligence Elements
It is a prospective, controlled, single-center, non-randomized, observational study. Two patient groups are planned for inclusion: the first - 200 patients with significant coronary artery stenosis confirmed by coronary angiography (CAG) or multislice computed tomography (MSCT) results; the second - a control group consisting of 200 patients without significant stenosis according to CAG or MSCT data.
All study subjects will have a date of coronary artery imaging via CAG or MSCT with assessment of myocardial perfusion.
Read more
Stress echocardiography tests or fractional flow reserve (FFR) assessment will be conducted as indicated.
All patients included in the study will undergo ECG recording within 1 month before or after CAG or MSCT in standard lead I for 1 minute, followed by spectral analysis of the obtained data, which will be stored at the remote monitoring center of Sechenov University without being linked to the personal data of patients. A spectral analysis of the electrocardiogram will be performed using a continuous wavelet transform.
The result of this study will be the identification of ECG parameters that correlate with significant coronary artery stenosis.
Read the detailed description
The aim of the study:: To develop and evaluate the diagnostic efficacy of a screening method for significant coronary artery stenosis based on data obtained from the analysis of a single-channel electrocardiogram.
This is a prospective, controlled, single-center, non-randomized, observational study. Two patient groups are planned for inclusion: the first group comprises 200 patients with significant coronary artery stenosis confirmed by coronary angiography (CAG) or multislice computed tomography (MSCT) results; the second group is a control group consisting of 200 patients without significant stenosis according to CAG or MSCT data.
All study subjects will have a date of coronary artery imaging via CAG or MSCT with assessment of myocardial perfusion. Stress echocardiography tests or fractional flow reserve (FFR) assessment will be conducted as clinically indicated. ECG registration in standard lead I will be performed within 3 months before or after the CAG or MSCT.
Obtained data will be stored at the remote monitoring center of Sechenov University without being linked to the personal data of patients. A spectral analysis of the electrocardiogram will be performed using a continuous wavelet transform.
The single-channel ECG will be recorded using the portable single-lead ECG monitor CardioQvark. It is designed as an iPhone cover. It is registered with the Federal Service for Health Surveillance on February 15, 2019. RZN No. 2019/8124.
The result of this study will be the identification of ECG parameters that correlate with significant coronary artery stenosis.
The patient's personal data (last name, first name, patronymic, date of birth, contact information) will not be transferred or taken into account. Each patient is assigned an individual number that is not associated with his/her personal data.
Subsequently, spectral analysis of the electrocardiogram will be performed using machine learning models and/or neural network data analysis.
Then a spectral analysis of the electrocardiogram will be performed using a continuous wavelet transform, the principles of which are based on the Fourier transform.
Analysis of the single-channel ECG involves evaluation of the following parameters (the parameters listed below will be calculated as median beat-to-beat values):
- TpTe - time from peak to end of the T-wave
- VAT - time from the beginning of the QRS to the R-peak
- QTc - corrected QT interval.
- QT/TQ - the ratio of QT length to TQ length (from the end of T to the beginning of the QRS of the next complex).
- QRS_E - total energy of the QRS-wave based on wavelet transform
- T_E - total energy of the T-wave based on wavelet transform
- TP_E - energy of the main T-wave peak based on wavelet transform
- BETA, BETA_S - T-wave asymmetry coefficients (simple and smoothed versions)
- BAD_T - flag of T-wave quality (whether expressed in the current lead)
- QRS_D1_ons - energy of the leading edge of the R-wave (based on the "first derivative" wavelet transform)
- QRS_D1_offs - energy of the trailing edge of the R-wave (based on the "first derivative" wavelet transform)
- QRS_D2 - peak energy of the R-wave (based on the "second derivative" wavelet transform)
- QRS_Ei (i=1,2,3,4) - QRS-wave energy in 4 frequency ranges (2-4-8-16-32 Hz) based on wavelet transform
- T_Ei (i=1,2,3,4) - T-wave energy in 4 frequency ranges (2-4-6-8-10 Hz) based on wavelet transform
- HFQRS - amplitude of the high-frequency components of the QRS-wave
Additionally used parameters:
- TpTe, VAT, QTc - are duplicated to control the correctness of record processing (the value of the central measure should be approximately equal to the beat-to-beat median).
- QRSw - QRS width.
- RA, SA, TA - amplitudes of the R, S, T-waves, respectively, used for normalizing the parameters listed above.
Method of statistical processing of results: SPSS Statistics Version 26 computer program for statistical data processing; construction of machine learning models and/or neural network data analysis The proposed research outcome: development of an algorithm for diagnosing significant coronary stenosis based on single-channel ECG data using elements of artificial intelligence.
The endpoints of the study are the parameters of diagnostic accuracy of the developed model:
- specificity,
- sensitivity,
- prognostic significance of a positive and negative result,
- diagnostic accuracy.
Тhese metrics will be calculated using receiver operating characteristic (ROC) analysis and confusion matrices on a held-out test set (30% of the dataset) after training multifactorial models (logistic regression, random forest, or neural networks) on single-lead ECG features. Sensitivity, specificity, positive/negative predictive values, and overall accuracy will be derived by comparing model predictions of significant coronary stenosis (≥50% lumen narrowing per CAG/MSCT) against the gold standard, with cross-validation (k=5 folds) to ensure robustness and bootstrap resampling for 95% confidence intervals.
- Conditions
- Ischemic Heart Disease, Coronary Artery Stenosis, Stable Angina Pectoris, Acute Coronary Syndromes
- Being tested
- single-channel electrocardiogram
- Keywords
- coronary, Ischemic Heart Disease, Single-Channel ECG, Artificial Intelligence, AI-Enhanced Screening, Non-Invasive Diagnostics, Angina
- Medical subject headings
- Myocardial Ischemia, Coronary Stenosis, Angina, Stable, Acute Coronary Syndrome, Angina Pectoris
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
single-channel electrocardiogramDiagnostic test
The single-channel ECG will be recorded using the portable single-lead ECG monitor CardioQvark. It is designed as an iPhone cover. It is registered with the Federal Service for Health Surveillance on February 15, 2019. RZN No. 2019/8124
| Study group | Role | What they receive |
|---|---|---|
| coronary artery stenosis | 200 patients with significant coronary artery stenosis confirmed by coronary angiography (CAG) or multislice computed tomography (MSCT) results Receives: Diagnostic Test: single-channel electrocardiogram | |
| control group | 200 patients without significant stenosis according to CAG or MSCT data Receives: Diagnostic Test: single-channel electrocardiogram |
What is being measured
The primary outcome is the main question the study is designed to answer.
Sensitivity, specificity, positive/negative predictive values, and overall accuracy
Sensitivity, specificity, positive/negative predictive values, and overall accuracy will be derived by comparing model predictions of significant coronary stenosis (≥50% lumen narrowing per CAG/MSCT) against the gold standard, with cross-validation (k=5 folds) to ensure robustness and bootstrap resampling for 95% confidence intervals.
Measured: From July 2027 to August 2027
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 May 2026
- Study start1 May 2026 (estimated)
- Primary completion1 Sep 2027 (estimated)
- Study completion1 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Ischemic Heart DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 400 participants (estimated)
Sponsor and investigators
- Lead sponsor
- I.M. Sechenov First Moscow State Medical University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07579624
- Sponsor's protocol ID
- ChPSH22261
- Status last verified
- Apr 2026
- First submitted
- 9 Feb 2026
- Last updated
- 12 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: It is not possible to provide documentation due to the prohibition received from the local ethics committee
Publications
Analysis of transitions between linear and nonlinear cardiac rhythm modes in patients with ischemic heart disease / L. V. Mezentseva, P. Sh. Chomakhidze, F. Yu. Kopylov [et al.] // Pathogenesis. - 2017. - Vol. 15, No. 1. - P. 54-58. - DOI 10.25557/GM.2017.1.6952. - EDN ZFALML.
Simakov, Sergey, Gamilov, Timur, Danilov, Alexander, Kopylov, Philipp, Chomakhidze, Peter and Liang, Fuyou. "Hemodynamics in residual myocardial ischemia". BIOKYBERNETIKA: Mathematics for Theory and Control in the Human and in Society, edited by Jochen Mau, Sergey Mukhin, Guanyu Wang and Shuhua Xu, Berlin, Boston: De Gruyter, 2025, pp. 319-334. https://doi.org/10.1515/9783111341996-017
Study at a glance
From the registry record, last updated by the sponsor on 12 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Screening for Significant Coronary Artery Stenosis Using Single-channel Electrocardiogram Analysis With Artificial Intelligence Elements
- ClinicalTrials.gov ID
- NCT07579624
- Acronym / sponsor ID
- ChPSH22261
- Conditions
- Ischemic Heart Disease, Coronary Artery Stenosis, Stable Angina Pectoris, Acute Coronary Syndromes
- Keywords
- coronary, Ischemic Heart Disease, Single-Channel ECG, Artificial Intelligence, AI-Enhanced Screening, Non-Invasive Diagnostics, Angina
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 400 participants (estimated)
- Lead sponsor
- I.M. Sechenov First Moscow State Medical UniversityUniversity, hospital or other
- Study start
- 1 May 2026 (estimated)
- Primary completion
- 1 Sep 2027 (estimated)
- Study completion
- 1 Dec 2027 (estimated)
- First posted
- 12 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
It is a prospective, controlled, single-center, non-randomized, observational study. Two patient groups are planned for inclusion: the first - 200 patients with significant coronary artery stenosis confirmed by coronary angiography (CAG) or multislice computed tomography (MSCT) results; the second - a control group consisting of 200 patients without significant stenosis according to CAG or MSCT data.
All study subjects will have a date of coronary artery imaging via CAG or MSCT with assessment of myocardial perfusion.
Stress echocardiography tests or fractional flow reserve (FFR) assessment will be conducted as indicated.
All patients included in the study will undergo ECG recording within 1 month before or after CAG or MSCT in standard lead I for 1 minute, followed by spectral analysis of the obtained data, which will be stored at the remote monitoring center of Sechenov University without being linked to the personal data of patients. A spectral analysis of the electrocardiogram will be performed using a continuous wavelet transform.
The result of this study will be the identification of ECG parameters that correlate with significant coronary artery stenosis.
Detailed description
The aim of the study:: To develop and evaluate the diagnostic efficacy of a screening method for significant coronary artery stenosis based on data obtained from the analysis of a single-channel electrocardiogram.
This is a prospective, controlled, single-center, non-randomized, observational study. Two patient groups are planned for inclusion: the first group comprises 200 patients with significant coronary artery stenosis confirmed by coronary angiography (CAG) or multislice computed tomography (MSCT) results; the second group is a control group consisting of 200 patients without significant stenosis according to CAG or MSCT data.
All study subjects will have a date of coronary artery imaging via CAG or MSCT with assessment of myocardial perfusion. Stress echocardiography tests or fractional flow reserve (FFR) assessment will be conducted as clinically indicated. ECG registration in standard lead I will be performed within 3 months before or after the CAG or MSCT.
Obtained data will be stored at the remote monitoring center of Sechenov University without being linked to the personal data of patients. A spectral analysis of the electrocardiogram will be performed using a continuous wavelet transform.
The single-channel ECG will be recorded using the portable single-lead ECG monitor CardioQvark. It is designed as an iPhone cover. It is registered with the Federal Service for Health Surveillance on February 15, 2019. RZN No. 2019/8124.
The result of this study will be the identification of ECG parameters that correlate with significant coronary artery stenosis.
The patient's personal data (last name, first name, patronymic, date of birth, contact information) will not be transferred or taken into account. Each patient is assigned an individual number that is not associated with his/her personal data.
Subsequently, spectral analysis of the electrocardiogram will be performed using machine learning models and/or neural network data analysis.
Then a spectral analysis of the electrocardiogram will be performed using a continuous wavelet transform, the principles of which are based on the Fourier transform.
Analysis of the single-channel ECG involves evaluation of the following parameters (the parameters listed below will be calculated as median beat-to-beat values):
- TpTe - time from peak to end of the T-wave
- VAT - time from the beginning of the QRS to the R-peak
- QTc - corrected QT interval.
- QT/TQ - the ratio of QT length to TQ length (from the end of T to the beginning of the QRS of the next complex).
- QRS_E - total energy of the QRS-wave based on wavelet transform
- T_E - total energy of the T-wave based on wavelet transform
- TP_E - energy of the main T-wave peak based on wavelet transform
- BETA, BETA_S - T-wave asymmetry coefficients (simple and smoothed versions)
- BAD_T - flag of T-wave quality (whether expressed in the current lead)
- QRS_D1_ons - energy of the leading edge of the R-wave (based on the "first derivative" wavelet transform)
- QRS_D1_offs - energy of the trailing edge of the R-wave (based on the "first derivative" wavelet transform)
- QRS_D2 - peak energy of the R-wave (based on the "second derivative" wavelet transform)
- QRS_Ei (i=1,2,3,4) - QRS-wave energy in 4 frequency ranges (2-4-8-16-32 Hz) based on wavelet transform
- T_Ei (i=1,2,3,4) - T-wave energy in 4 frequency ranges (2-4-6-8-10 Hz) based on wavelet transform
- HFQRS - amplitude of the high-frequency components of the QRS-wave
Additionally used parameters:
- TpTe, VAT, QTc - are duplicated to control the correctness of record processing (the value of the central measure should be approximately equal to the beat-to-beat median).
- QRSw - QRS width.
- RA, SA, TA - amplitudes of the R, S, T-waves, respectively, used for normalizing the parameters listed above.
Method of statistical processing of results: SPSS Statistics Version 26 computer program for statistical data processing; construction of machine learning models and/or neural network data analysis The proposed research outcome: development of an algorithm for diagnosing significant coronary stenosis based on single-channel ECG data using elements of artificial intelligence.
The endpoints of the study are the parameters of diagnostic accuracy of the developed model:
- specificity,
- sensitivity,
- prognostic significance of a positive and negative result,
- diagnostic accuracy.
Тhese metrics will be calculated using receiver operating characteristic (ROC) analysis and confusion matrices on a held-out test set (30% of the dataset) after training multifactorial models (logistic regression, random forest, or neural networks) on single-lead ECG features. Sensitivity, specificity, positive/negative predictive values, and overall accuracy will be derived by comparing model predictions of significant coronary stenosis (≥50% lumen narrowing per CAG/MSCT) against the gold standard, with cross-validation (k=5 folds) to ensure robustness and bootstrap resampling for 95% confidence intervals.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| coronary artery stenosis | – | Diagnostic Test: single-channel electrocardiogram200 patients with significant coronary artery stenosis confirmed by coronary angiography (CAG) or multislice computed tomography (MSCT) results |
| control group | – | Diagnostic Test: single-channel electrocardiogram200 patients without significant stenosis according to CAG or MSCT data |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- All study subjects will have a date of coronary artery imaging via CAG or MSCT with assessment of myocardial perfusion. Stress echocardiography tests or fractional flow reserve (FFR) assessment will be conducted as clinically indicated. ECG registration in standard lead I will be performed within 3 months before or after the CAG or MSCT.
Key inclusion criteria (7 listed)
- Presence of written informed consent from the patient to participate in the study.
- Age 18 years and older.
- Outpatient visit and/or hospitalization at the research center with coronary visualization performed.
- Absence of sufficient data on coronary anatomy and stenosis significance.
- Any conditions impairing the quality of single-channel ECG recording (Parkinson's disease, essential tremor, and others).
Key exclusion criteria (3 listed)
- Patient's unwillingness to continue participation in the study.
- Inability to perform full analysis of single-channel ECG digital characteristics.
- Refusal of coronary visualization methods for any reason.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| single-channel electrocardiogramThe single-channel ECG will be recorded using the portable single-lead ECG monitor CardioQvark. It is designed as an iPhone cover. It is registered with the Federal Service for Health Surveillance on February 15, 2019. RZN No. 2019/8124 | Diagnostic test | control group, coronary artery stenosis |
Primary outcome
Sensitivity, specificity, positive/negative predictive values, and overall accuracy
Time frame: From July 2027 to August 2027
Sensitivity, specificity, positive/negative predictive values, and overall accuracy will be derived by comparing model predictions of significant coronary stenosis (≥50% lumen narrowing per CAG/MSCT) against the gold standard, with cross-validation (k=5 folds) to ensure robustness and bootstrap resampling for 95% confidence intervals.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 May 2026.
- BackgroundAnalysis of transitions between linear and nonlinear cardiac rhythm modes in patients with ischemic heart disease / L. V. Mezentseva, P. Sh. Chomakhidze, F. Yu. Kopylov [et al.] // Pathogenesis. - 2017. - Vol. 15, No. 1. - P. 54-58. - DOI 10.25557/GM.2017.1.6952. - EDN ZFALML.
- BackgroundSimakov, Sergey, Gamilov, Timur, Danilov, Alexander, Kopylov, Philipp, Chomakhidze, Peter and Liang, Fuyou. "Hemodynamics in residual myocardial ischemia". BIOKYBERNETIKA: Mathematics for Theory and Control in the Human and in Society, edited by Jochen Mau, Sergey Mukhin, Guanyu Wang and Shuhua Xu, Berlin, Boston: De Gruyter, 2025, pp. 319-334. https://doi.org/10.1515/9783111341996-017
- Individual participant dataSharing planned: No. It is not possible to provide documentation due to the prohibition received from the local ethics committee
Related trials for Ischemic Heart Disease
Not yet recruitingPhase 4
Roxadustat and Myocardial Injury After Off-Pump Coronary Artery Bypass Surgery
Coronary Artery Disease, Coronary Artery Bypass Grafting
RecruitingObservational study
Preoperative Gastric Ultrasound and Left Ventricular Function in Coronary Artery Bypass Surgery
Coronary Artery Disease, Left Ventricular Systolic Dysfunction
Active, not recruiting
Assessment of Combined CCM and ICD Device in HFrEF
Heart Failure, Heart Failure With Reduced Ejection Fraction
Active, not recruiting
The OCTOBER Trial - European Trial on Optical Coherence Tomography Optimized Bifurcation Event Reduction (OCTOBER)
Ischaemic Heart Disease, Ischemic Heart Disease
RecruitingEarly Phase 1
Thiamine Intervention and Coronary Artery Bypass Grafting
Coronary Heart Disease, Coronary Artery Bypass Grafting
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Ischemic Heart Disease and Coronary Artery Stenosis, run by I.M. Sechenov First Moscow State Medical University at 1 site in Russia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 12 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Russia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Petr Chomakhidze, Professor (+79166740369, chomakhidze_p_sh@staff.sechenov.ru), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Sensitivity, specificity, positive/negative predictive values, and overall accuracy (time frame: From July 2027 to August 2027). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07579624, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 May 2026.